Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
TipRanks
22.22%
Finnhub
22.22%
GlobeNewswire
11.11%
Others
44.44%
•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
82
IPO Date
Nov 8, 2006
Country
US
Industry
Health Care
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals announced that its sub-licensee in Japan, DyDo Pharma, has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo’s New Drug Application to commercialize FIRDAPSE Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome in Japan.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with CPRX
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Very Bearish